Tait Davis Shanafelt
Physician at 1 St, Rochester, MN
License number
Colorado 53269
Issued Date
Dec 11, 2013
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
200 1St St SW, Rochester, MN 55905
Professional information
Dr. Tait D Shanafelt, Rochester MN - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Hematology, 2005, Internal Medicine, 2001, Medical Oncology, 2004
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
200 1St St SW, Rochester 55905
Mayo Clinic Saint Marys Hospital
1216 2Nd St South #West, Rochester 55902
North Memorial Medical Center
3300 Oakdale Ave North, Robbinsdale 55422
Education:
Medical School
Co-Operative Medical College, Kochi, Kochi University
Graduated: 1998
Mayo Grad School Med/Mayo Fndn
University Of Wa School Of Med
Co-Operative Medical College, Kochi, Kochi University
Graduated: 1998
Mayo Grad School Med/Mayo Fndn
University Of Wa School Of Med
Tait Shanafelt, Rochester MN
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Methods Of Treating Hematologic Cancers
US Patent:
2012019, Jul 26, 2012
Filed:
Jul 27, 2010
Appl. No.:
13/388751
Inventors:
Neil E. Kay - St. Louis Park MN, US
Tait D. Shanafelt - Rochester MN, US
Tait D. Shanafelt - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
A61K 31/7076, A61P 35/00, A61P 35/02, A61K 31/353
US Classification:
514 47, 514456
Abstract:
This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.